Thirty-six per cent would prescribe whilst a patient was waiting for macular laser, 23% would wait until 2 weeks after macular laser while 41 % would delay prescription for 3 months after macular photocoagulation. Twelve eyes of 12 diabetics (6 non-insulin-dependent and 6 insulin-dependent) were included in the refraction study. There were 8 female and 4 male subjects. The median age of the subjects was 59.5 years (interquartile range 46-68.5) with a median duration of diabetes of 10.5 years (interquartile range 2.5-16.5). Five subjects were emmetropic, 3 were myopic and 4 hyperopic at baseline pre-laser refraction. The visual acuity for subjective refraction throughout the study recorded a mean acuity of 6/9 (range 6/4 to 6/18). Each eye received an average of 92 (SD 105) burns (either focal or grid). There were 8 patients with unilateral CSMO and their fellow eyes were used as controls. At 3 months after photocoagulation, slit-lamp biomicroscopy revealed all but 1 patient to have a dry macula. The patient who had suspected residual oedema (subject 8 in Table 1 ) responded to further macular photocoagulation at 4 months follow-up. Table 1 shows the SEQ of the refraction at various times during the study for the photocoagulated eyes. The median change in absolute magnitude of SEQ was 0.36 D at 4-6 weeks post-laser (interquartile range 0.18-0.50 D).
affecting up to a quarter of the diabetic population} is often diagnosed by optometrists2 and referred to hospital ophthalmic departments where appropriate photocoagulation treatmene can be performed.
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Many of these patients have had difficulty reading or have experienced a change in their refraction since their last optometric/ ophthalmic assessment. However, it is our experience that a common practice among health care providers in the UK is to delay prescription of new lenses until maculopathy has been 'treated'. To test this suspicion, we performed a questionnaire survey of consultant ophthalmologists in our Region (Trent).
As far as we are aware, there has been no study documenting a significant change of refraction as a result of macular photocoagulation alone. If such treatment does not alter refractive status to any practical extent, spectacles can be prescribed without delay whenever required, even on detection of diabetic maculopathy.
In order to address the possible change in refraction from macular photocoagulation, we conducted a prospective controlled study on a group of diabetic patients who were scheduled for photocoagulation in order to treat diabetic maculopathy.
Methods
The qeustionnaire survey was carried out by a postal method. All 59 consultant ophthalmologists from Trent Region were sent a questionnaire (see Appendix). Thirty-six per cent would prescribe whilst a patient was waiting for macular laser, 23% would wait until 2 weeks after macular laser while 41 % would delay prescription for 3 months after macular photocoagulation. Twelve eyes of 12 diabetics (6 non-insulin-dependent and 6 insulin-dependent) were included in the refraction study. There were 8 female and 4 male subjects. The median age of the subjects was 59.5 years (interquartile range 46-68.5) with a median duration of diabetes of 10.5 years (interquartile range 2.5-16.5). Five subjects were emmetropic, 3 were myopic and 4 hyperopic at baseline pre-laser refraction. The visual acuity for subjective refraction throughout the study recorded a mean acuity of 6/9 (range 6/4 to 6/18). Each eye received an average of 92 (SD 105) burns (either focal or grid). There were 8 patients with unilateral CSMO and their fellow eyes were used as controls. At 3 months after photocoagulation, slit-lamp biomicroscopy revealed all but 1 patient to have a dry macula. The patient who had suspected residual oedema (subject 8 in Table 1 ) responded to further macular photocoagulation at 4 months follow-up. Table 1 shows the SEQ of the refraction at various times during the study for the photocoagulated eyes. The median change in absolute magnitude of SEQ was 0.36 D at 4-6 weeks post-laser (interquartile range 0.18-0.50 D).
With the Wilcoxon signed-rank test, there was no statistically significant change in refraction at 4-6 weeks following laser photocoagulation (p = 0.17). At 4 months post-laser, the median SEQ absolute magnitude change 
Average of 1st Post-laser and Pre-laser SEQ (0) 1 and 2. The correlation coefficient for first follow-up data was 0.02 (95% CI -0.14 to 0.19, P = 0.75) and that of the second follow-up was 0.11 (95% CI -0.06 to 0.28, P = 0.17). Both correlation coefficients are very close to zero, confirming that there was no tendency for alteration in refraction with initial ametropia.
Discussion
Our questionnaire survey confirmed that the majority of consultant ophthalmologists would defer prescription of spectacles until after diabetic patients have received argon laser treatment for diabetic maculopathy. One can imagine that, in some cases, the management of diabetic maculopathy can result in delays for optimal refractive correction of over a year following initial diagnosis. This B � 2.0
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Scatter-plot of the diff erence between the 2nd post-laser SEQ and pre-laser SEQ against their average with 95% limits and regression line.
has important implications for patients whose newly corrected distance visual acuity would have allowed them to drive, as field loss from bilateral macular laser is almost never significant enough to result in the patient failing the DVLA field regulation?
The refraction study was of prospective design with uniform test conditions and treatment. There are some limitations, however, including the small subject numbers and a relatively short follow-up period.
Although our study was only a pilot, we nevertheless found no significant change in refractive error following laser treatment in diabetic maculopathy. We excluded patients who had pan-retinal photocoagulation as this can potentially cause temporary cycloplegia8 which might influence the refraction. In addition, our study only includes type 2 diabetics, but it is this subgroup who constitute the majority of patients requiring macular treatment alone. Although the sample was small, our pilot study does cover a wide age range and includes both insulin and non-insulin-dependent diabetics. Our cohort of patients appears to be representative of patients undergoing macular laser treatment. This pilot study could be
